TITLE

In sickness and in health

AUTHOR(S)
Boyce, Nell
PUB. DATE
October 1997
SOURCE
New Scientist;10/25/97, Vol. 156 Issue 2105, p20
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the impact of gene therapy trials approved by the Recombinant DNA Advisory Committee of the US National Institutes of Health. Debate on the prevention of genetic engineering that changes normal characteristics; Effect of gene therapy on future generations; Risks of altering genetic traits in healthy humans.
ACCESSION #
13112

 

Related Articles

  • Fears mount for gene scrutiny as watchdog faces axe. Kiernan, Vincent // New Scientist;6/08/96, Vol. 150 Issue 2033, p10 

    Reports on the proposed abolition of the US Recombinant DNA Advisory Committee (RAC) that was originally tasked to lay down guidelines for genetic engineering experiments in bacteria. Approval of human gene therapy trials; Transfer of RAC tasks to the Food and Drug Administration and review...

  • NIH review to suggest streamlined handling of gene therapy bids. Taylor, Robert // Nature;6/29/1995, Vol. 375 Issue 6534, p713 

    Reports on the conclusion made by an external advisory panel that the Recombinant DNA Advisory Committee (RAC) of the United States National Institutes of Health (NIH) need not review human gene therapy protocols similar to those already approved. Initial screening of applications to be made...

  • Researchers seek guidance on "preproposal" for in utero gene therapy. Jenks, Susan; Jenks, S // JNCI: Journal of the National Cancer Institute;10/21/98, Vol. 90 Issue 20, p1507 

    Presents information on a `preproposal' for in utreo gene therapy, which is being discussed before the Recombinant DNA Advisory Committee (RAC) by W. French Anderson, of the University of Southern California and Esmail Zanjani, of the University of Nevada. Information on gene therapy; Details...

  • Review panel cancels meeting as gene therapy proposals fall. Wadman, Meredith // Nature;2/22/1996, Vol. 379 Issue 6567, p668 

    Presents the reasons for the decline in gene therapy protocols. Cancellation of the March 1996 meeting by the 25-member Recombinant DNA Advisory Committee on the grounds that it does not have any protocols to review; Explanation of the decline as the pause in research as it moves from one level...

  • Keeping faith in gene manipulation.  // Nature;7/18/1996, Vol. 382 Issue 6588, p191 

    Asserts that good reasons exist for revising the way the gene therapy experiments receive public scrutiny, but such revision must be done sensitively. The controversial role in the scientific community of the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health...

  • US plan to scrap DNA panel splits genetic researchers. Wadman, Meredith // Nature;7/18/1996, Vol. 382 Issue 6588, p197 

    Reports disputes in the American gene-therapy field over a proposal to eliminate the Recombinant DNA Advisory Committee (RAC) of the US National Institutes of Health (NIH). Creation of the committee in the mid-1970s, in response to public fears of genetic engineering; The NIH's view that the...

  • Gene therapy for lung cancer still on hold. Jenks, Susan // JNCI: Journal of the National Cancer Institute;4/6/94, Vol. 86 Issue 7, p486 

    Reports on the conditional approval granted by the National Institutes of Health Recombinant DNA Advisory Committee to the study on the proposed gene therapy for lung cancer during the March 3-4, 1994 meeting. Reason given for the conditional approval; Call for more data to be presented;...

  • Future tense for in utero gene therapy. Fox, Jeffrey L. // Nature Biotechnology;Nov98, Vol. 16 Issue 11, p1002 

    Focuses on plans of the U.S. National Institutes of Health Recombinant DNA Advisory Committee (NIHRAC) related to the research proposal for in utero gene therapy. Plans of French Anderson of the University of Southern California School of Medicine and researchers related to in utero correction...

  • Gene therapy inquiry. Fox, Jeff // Nature Biotechnology;Jan2000, Vol. 18 Issue 1, p8 

    Reports on a gene therapy inquiry conducted by the U.S. National Institutes of Health Recombinant DNA Advisory Committee and the U.S. Food and Drug Administration in December 1999. Discussion on adverse event reporting requirements with which gene therapy researchers are asked to comply;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics